Th22, but not Th17 Might be a Good Index to Predict the Tissue Involvement of Systemic Lupus Erythematosus

Xuyan Yang(Second Affiliated Hospital of Zhejiang University), Qingqing Wang, Lijuan Wang, Qinghua Lv(Zhejiang Cancer Hospital), Huiying Wang(Second Affiliated Hospital of Zhejiang University), Xiaoying Zhao(Handan College)

Journal of Clinical Immunology

February 22, 2013

10.1007/s10875-013-9878-1

Cited by 66

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247

Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis

|BMC Cancer|2014|146

Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

|PLoS ONE|2015|115